Sanai Health Industry Group Company Aktie

Sanai Health Industry Group Company für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2H63V / ISIN: KYG7785S1075

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
12.09.2025 06:30:12

Hong Kong Lab Zentrogene Cracks Twin DNA Code; Gender Mystery Solved for Moms Worldwide


EQS Newswire / 12/09/2025 / 06:30 CET/CEST

HONG KONG SAR - Media OutReach Newswire - 12 September 2025 - Zentrogene Laboratory, an international genetic testing institution based in Hong Kong (under Sanai Health Industry Group 01889.HK), announced the launch of its 'Y Precision' testing technology based on Next-Generation Sequencing (NGS). This locally developed innovation in Hong Kong addresses longstanding industry challenges in gender determination for twin pregnancies. It overcomes the limitations of traditional qPCR platforms, achieving the first-ever precise identification of male-female twins while significantly enhancing the accuracy of fetal cell-free DNA (cfDNA) analysis.

671820-image-1-png-550x.png
Illustration: IP Image Ambassador Dr.z

Traditional methods could only qualitatively detect the presence of the Y chromosome, failing to distinguish between male-male twins and male-female twins. They also lacked the capability to identify residual male cfDNA after fetal reduction procedures. Zentrogene's NGS-based technology achieves three breakthroughs:
  1. Fetal Signal Assessment: Utilizes whole-genome SNP scanning to confirm fetal signal presence, precisely quantify fetal fraction, and determine the number of fetal signals.
  2. Contamination Identification: Differentiates between false signals (e.g., contamination-derived Y chromosome fragments) and true fetal signals.
  3. Twin Pregnancy Precision Analysis: Independently analyzes X and Y chromosome fragments to accurately distinguish male-female twins from male-male twins.
As a pioneer in Hong Kong's genetic testing field, Zentrogene has established a global technology matrix covering pre-pregnancy, prenatal, and oncology applications through its integrated Sanger sequencing and NGS platforms. This NGS breakthrough underscores its 'Technology-Driven Globalization' strategy, leveraging Hong Kong's expertise to deliver precision medical solutions worldwide. Zentrogene continues to advance genetic technology, safeguarding every family's hopes with scientific rigor.

For details, visit:
https://www.zentrogene.com/
https://www.zentrogene.com.hk/

Official Cooperation Contacts:
Telephone: +86 18051865085 (WeChat same number)
Telegram: +855 99990026
Facebook: Zentrogene

Hashtag: #Zentrogene

The issuer is solely responsible for the content of this announcement.

225647
News Source: Zentrogene

12/09/2025 Dissemination of a Financial Press Release, transmitted by EQS News.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

Nachrichten zu Sanai Health Industry Group Company Limited Registered Shsmehr Nachrichten

Analysen zu Sanai Health Industry Group Company Limited Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!